US 12,227,764 B2
Pepmixes to generate multiviral CTLs with broad specificity
Ann Marie Leen, Houston, TX (US); Juan Fernando Vera Valdes, Bellaire, TX (US); Cliona M. Rooney, Houston, TX (US); and Ulrike Gerdemann, Cambridge, MA (US)
Assigned to Baylor College of Medicine, Houston, TX (US)
Filed by Baylor College of Medicine, Houston, TX (US)
Filed on Jul. 23, 2021, as Appl. No. 17/443,261.
Application 17/443,261 is a continuation of application No. 15/905,176, filed on Feb. 26, 2018, granted, now 11,118,164.
Application 15/905,176 is a continuation of application No. 14/377,825, abandoned, previously published as PCT/US2013/025342, filed on Feb. 8, 2013.
Claims priority of provisional application 61/596,875, filed on Feb. 9, 2012.
Prior Publication US 2021/0348127 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); C07K 14/025 (2006.01); C07K 14/03 (2006.01); C07K 14/11 (2006.01); C07K 14/135 (2006.01); C12N 7/00 (2006.01)
CPC C12N 5/0638 (2013.01) [A61K 39/12 (2013.01); A61K 39/4611 (2023.05); A61K 39/464838 (2023.05); C07K 14/025 (2013.01); C07K 14/03 (2013.01); C07K 14/11 (2013.01); C07K 14/135 (2013.01); C12N 7/00 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2039/577 (2013.01); A61K 2039/70 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16234 (2013.01); Y02A 50/30 (2018.01)] 21 Claims
 
1. A method of providing a cell therapy to an individual in need thereof, comprising administering a composition to the individual, wherein the composition comprises an ex vivo expanded polyclonal population of cytotoxic human T lymphocytes (CTLs) that target two or more viral antigens from two or more different viruses, wherein the CTLs are polyclonal CD4+ and CD8+ CTLs;
wherein one or more antigens is from a first virus, and one or more antigens is from a second virus; and wherein
(a) the first virus is BK virus, and the one or more antigens are selected from LT and VP-1; and
(b) the second virus is HHV6 virus, and the one or more antigens are selected from U14, U11, U71, U54, and U90.